[
1. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003, 3(1).35-45.
]Search in Google Scholar
[
2. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009, 21(2).215-223.
]Search in Google Scholar
[
3. Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol. 2016, 104(1).6-17.
]Search in Google Scholar
[
4. Wang X, Riviere I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015, 22(2).85-94.
]Search in Google Scholar
[
5. Davila ML, Brentjens R, Wang X et al. How do CARs work? Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012, 1(9).1577-1583.
]Search in Google Scholar
[
6. Maher J, Brentjens RJ, Gunset G et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002, 20(1).70-75.
]Search in Google Scholar
[
7. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20).4099-4102.
]Search in Google Scholar
[
8. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119(12).2709-2720.
]Search in Google Scholar
[
9. Li YS, Wasserman R, Hayakawa K et al. Identification of the earliest B lineage stage in mouse bone marrow. Immunity 1996, 5(6).527-535.
]Search in Google Scholar
[
10. Jensen MC, Popplewell L, Cooper LJ et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of blood and marrow transplantation. Biol Blood Marrow Transplant. 2010, 16(9).1245-1256.
]Search in Google Scholar
[
11. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011, 121(5).1822-1826.
]Search in Google Scholar
[
12. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011, 3(95).95ra73.
]Search in Google Scholar
[
13. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011, 365(8).725-733.
]Search in Google Scholar
[
14. Kloss CC, Condomines M, Cartellieri M et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013, 31(1).71-75.
]Search in Google Scholar
[
15. Lanitis E, Poussin M, Klattenhoff AW et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013, 1(1).43-53.
]Search in Google Scholar
[
16. Lupo-Stanghellini MT, Provasi E, Bondanza A et al. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther. 2010, 21(3).241-250.
]Search in Google Scholar
[
17. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011, 365(18).1673-1683.
]Search in Google Scholar
[
18. Fire A, Xu S, Montgomery MK, Kostas SA et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669).806-811.
]Search in Google Scholar
[
19. Khoury M, Louis-Plence P, Escriou V et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 2006, 54(6).1867-1877.
]Search in Google Scholar
[
20. Fleischmann KK, Pagel P, Schmid I et al. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. Mol. Cancer 2014, 13.27.
]Search in Google Scholar
[
21. Lagresle-Peyrou C, Lefrere F, Magrin E et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica 2018, 103(5).778-786.
]Search in Google Scholar
[
22. Pantin J, Purev E, Tian X et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors. results of a randomized crossover trial. Haematologica 2017, 102(3).600-609.
]Search in Google Scholar
[
23. Adair JE, Sevilla J, Heredia CD et al. Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Current Gene Therapy 2017, 16(5).338-348.
]Search in Google Scholar
[
24. Passweg JR, Baldomero H, Bader P et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant.2018, 53(9).1139-1148.
]Search in Google Scholar
[
25. Booth C, Gaspar HB, Thrasher AJ. Treating Immunodeficiency through HSC Gene Therapy. Trends Mol Med. 2016, 22(4).317-327.
]Search in Google Scholar
[
26. Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Molecular Medicine 2017, 9(6).737-740.
]Search in Google Scholar
[
27. Cicalese MP, Ferrua F, Castagnaro L et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood 2016, 128(1).45-54.
]Search in Google Scholar
[
28. Thompson AA, Walters MC, Kwiatkowski J et al. Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med. 2018, 378(16).1479-1493.
]Search in Google Scholar
[
29. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells. generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci U S A. 1984, 81(20).6349-6353.
]Search in Google Scholar
[
30. Bregni M, Magni M, Siena S et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 1992, 80(6).1418-1422.
]Search in Google Scholar
[
31. Beatty MS, Curiel DT. Chapter two--Adenovirus strategies for tissue-specific targeting. Adv Cancer Res. 2012;115:39-67.
]Search in Google Scholar
[
32. Puntel M, A KMG, Farrokhi C, Vanderveen N et al. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicology and Applied Pharmacology 2013, 268(3).318-330.
]Search in Google Scholar
[
33. Nienhuis AW. Development of gene therapy for blood disorders. an update. Blood 2013, 122(9).1556-1564.
]Search in Google Scholar
[
34. Xiao PJ, Lentz TB, Samulski RJ. Recombinant adeno-associated virus. clinical application and development as a genetherapy vector. Therapeutic Delivery 2012, 3(7).835-856.
]Search in Google Scholar
[
35. Nathwani AC, Rosales C, McIntosh J et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Molecular therapy: The journal of the American Society of Gene Therapy 2011, 19(5).876-885.
]Search in Google Scholar
[
36. Erlwein O, McClure MO. Progress and prospects. foamy virus vectors enter a new age. Gene Ther. 2010, 17(12).1423-1429.
]Search in Google Scholar
[
37. Kaufmann KB, Brendel C, Suerth JD et al. Alpharetroviral vector-mediated gene therapy for X-CGD. functional correction and lack of aberrant splicing. Molecular therapy: The journal of the American Society of Gene Therapy 2013, 21(3).648-661.
]Search in Google Scholar
[
38. Corrigan-Curay J, Cohen-Haguenauer O, O’Reilly M et al. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Molecular therapy: The journal of the American Society of Gene Therapy 2012, 20(6).1084-1094.
]Search in Google Scholar
[
39. Smith BD, Kasamon YL, Kowalski J et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clinical Cancer Research. 2010, 16(1).338-347.
]Search in Google Scholar
[
40. Kawai T, Akira S. Innate immune recognition of viral infection. Nature Immunol. 2006, 7(2).131-137.
]Search in Google Scholar
[
41. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunol. 2004, 5(10).987-995.
]Search in Google Scholar
[
42. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102(7).2660-2669.
]Search in Google Scholar
[
43. Supajatura V, Ushio H, Nakao A et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002; 109(10).1351-1359.
]Search in Google Scholar
[
44. Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci U S A. 2016, 113(7).E874-883.
]Search in Google Scholar
[
45. Gupta RM, Musunuru K. Expanding the genetic editing tool kit. ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014, 124(10).4154-4161.
]Search in Google Scholar
[
46. Kebriaei P, Izsvak Z, Narayanavari SA et al. Gene Therapy with the Sleeping Beauty Transposon System. Trends Genet. TIG 2017, 33(11).852-870.
]Search in Google Scholar
[
47. Kebriaei P, Singh H, Huls MH et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. The Journal of Clinical Investigation 2016, 126(9).3363-3376.
]Search in Google Scholar
[
48. Czechowicz A, Kraft D, Weissman IL et al. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007, 318(5854).1296-1299.
]Search in Google Scholar
[
49. Chhabra A, Ring AM, Weiskopf K et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine 2016, 8(351).351ra105.
]Search in Google Scholar
[
50. Palchaudhuri R, Saez B, Hoggatt J et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nature Biotechnology 2016, 34(7).738-745.
]Search in Google Scholar
